A
Amneal Pharmaceuticals
One of the most dynamic pharmaceutical companies in our industry
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, founded in 2002 by brothers Chirag and Chintu Patel, is a global pharmaceutical company dedicated to providing high-quality, innovative medicines. The company operates in major markets including the U.S., India, China, Europe, and Canada. Amneal's mission is to make healthcare accessible and improve the quality of life for patients worldwide.
Amneal serves a diverse range of clients, including healthcare providers, pharmacies, and patients. The company specializes in both generic and specialty medicines, ensuring that essential drugs are available at affordable prices. In India, Amneal entered the market in late 2022, focusing on delivering specialty medicines to Indian patients and families.
The company operates in the pharmaceutical industry, which is highly regulated and competitive. Amneal's business model revolves around the development, manufacturing, and distribution of pharmaceutical products. It generates revenue by selling these products to healthcare providers, pharmacies, and directly to patients. Additionally, Amneal engages in product donations to support low-income patients, disaster relief efforts, and global humanitarian needs.
Amneal's growth strategy includes expanding its product portfolio through acquisitions and partnerships. For instance, the company has acquired multiple Abbreviated New Drug Applications (ANDAs) and manufacturing facilities to bolster its production capabilities. This approach not only enhances its market presence but also ensures a steady pipeline of new products.
The company's commitment to social and environmental causes is evident through its philanthropic activities. Amneal has donated over 19 million doses of essential medicines to organizations like Dispensary of Hope, supporting those in greatest need.
In summary, Amneal Pharmaceuticals is a key player in the global pharmaceutical market, dedicated to making healthcare accessible through high-quality, affordable medicines and active community support.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1995
- Headquarters
- Bridgewater Township, United States
- Listing
- IPO 1995
- Employees
- 7,597
- Open positions
- 206
- Dealroom signal
- 92.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Packaging and Containers, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 4 companies, latest Apr 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jul 2026 | $2.4B | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Aug 2025 | $2.1B | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Amneal Pharmaceuticals is 41K monthly website visits, down 16.3% over the last three months. Amneal Pharmaceuticals's team grew 28% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kashiv BioSciencesBridgewater Township, United StatesNext-generation biosimilars and drug delivery for global healthcare.
$750Mvaluation
Punishka HealthcareIndia
→
Kashiv Specialty PharmaceuticalsBridgewater Township, United StatesAdvanced drug delivery and biosimilar platform for complex therapeutics. A subsidiary of Kashiv BioSciences acquired by Amneal
$102Mvaluation
AvKAREPulaski, United StatesAvKARE supports the health and medical needs by providing the highest quality, competitively priced generic Pharmaceuticals
$340Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Fidelity Investments
TPG
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amneal Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amneal Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.